Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank

被引:90
|
作者
Pilling, Luke C. [1 ]
Tamosauskaite, Jone [1 ]
Jones, Garan [1 ]
Wood, Andrew R. [2 ]
Jones, Lindsay [1 ]
Kuo, Chai-Ling [3 ]
Kuchel, George A. [4 ]
Ferrucci, Luigi [5 ]
Melzer, David [1 ,4 ]
机构
[1] Univ Exeter, Sch Med, RD&E Wonford, Epidemiol & Publ Hlth Grp, Exeter EX2 5DW, Devon, England
[2] Univ Exeter, Sch Med, Genet Complex Traits Grp, Exeter, Devon, England
[3] Univ Connecticut, Ctr Hlth, Biostat Ctr, CT Inst Clin & Translat Sci, Farmington, CT USA
[4] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT 06030 USA
[5] NIA, Baltimore, MD 21224 USA
来源
BMJ-BRITISH MEDICAL JOURNAL | 2019年 / 364卷
基金
欧洲研究理事会; 英国医学研究理事会; 美国国家卫生研究院;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; HFE C282Y HOMOZYGOSITY; IRON-OVERLOAD; INCREASED RISK; POPULATION; PENETRANCE; REPLACEMENT; PREVALENCE; DISEASE; MUTATIONS;
D O I
10.1136/bmj.k5222
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To compare prevalent and incident morbidity and mortality between those with the HFE p.C282Y genetic variant (responsible for most hereditary haemochromatosis type 1) and those with no p.C282Y mutations, in a large UK community sample of European descent. DESIGN Cohort study. SETTING 22 centres across England, Scotland, and Wales in UK Biobank (2006-10). PARTICIPANTS 451 243 volunteers of European descent aged 40 to 70 years, with a mean follow-up of seven years (maximum 9.4 years) through hospital inpatient diagnoses and death certification. MAIN OUTCOME MEASURE Odds ratios and Cox hazard ratios of disease rates between participants with and without the haemochromatosis mutations, adjusted for age, genotyping array type, and genetic principal components. The sexes were analysed separately as morbidity due to iron excess occurs later in women. RESULTS Of 2890 participants homozygous for p.C282Y (0.6%, or 1 in 156), haemochromatosis was diagnosed in 21.7% (95% confidence interval 19.5% to 24.1%, 281/1294) of men and 9.8% (8.4% to 11.2%, 156/1596) of women by end of follow-up. p.C282Y homozygous men aged 40 to 70 had a higher prevalence of diagnosed haemochromatosis (odds ratio 411.1, 95% confidence interval 299.0 to 565.3, P<0.001), liver disease (4.30, 2.97 to 6.18, P<0.001), rheumatoid arthritis (2.23, 1.51 to 3.31, P<0.001), osteoarthritis (2.01, 1.71 to 2.36, P<0.001), and diabetes mellitus (1.53, 1.16 to 1.98, P=0.002), versus no p.C282Y mutations (n=175 539). During the seven year follow-up, 15.7% of homozygous men developed at least one incident associated condition versus 5.0% (P<0.001) with no p.C282Y mutations (women 10.1% v 3.4%, P<0.001). Haemochromatosis diagnoses were more common in p.C282Y/p.H63D heterozygotes, but excess morbidity was modest. CONCLUSIONS In a large community sample, HFE p.C282Y homozygosity was associated with substantial prevalent and incident clinically diagnosed morbidity in both men and women. As p.C282Y associated iron overload is preventable and treatable if intervention starts early, these findings justify re-examination of options for expanded early case ascertainment and screening.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Contribution of rare genetic variants to heart failure and cardiomyopathy in the UK Biobank
    Zoller, Bengt
    Manderstedt, Eric
    Lind-Hallden, Christina
    Hallden, Christer
    ESC HEART FAILURE, 2023, 10 (05): : 3234 - 3235
  • [32] Canalization of the Polygenic Risk for Common Diseases and Traits in the UK Biobank Cohort
    Nagpal, Sini
    Tandon, Raghav
    Gibson, Greg
    MOLECULAR BIOLOGY AND EVOLUTION, 2022, 39 (04)
  • [33] Risk of hepatocellular carcinoma associated with genetic haemochromatosis in the absence of cirrhosis: A retrospective cohort study
    Dale, S. P.
    Aithal, G. P.
    Thomas, J. A.
    Zaitoun, A.
    Ryder, S. D.
    James, M. W.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S88 - S88
  • [34] Genetic testing for hereditary hyperparathyroidism in a large UK cohort
    Mariathasan, S.
    Andrews, K.
    Thompson, E.
    Challis, B.
    Wilcox, S.
    Pierce, H.
    Hale, J.
    Spiden, S.
    Fuller, G.
    Simpson, H.
    Fish, B.
    Jani, P.
    Seetho, I.
    Armstrong, R.
    Izatt, L.
    Joshi, M.
    Velusami, A.
    Casey, R.
    Park, S.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 228 - 228
  • [35] Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
    Sumpter, Nicholas
    Cadzow, Murray
    So, Alexander
    Reynolds, Richard
    Merriman, Tony
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [36] Loneliness and social isolation are associated with an increased risk of glaucoma: a UK Biobank cohort study
    Zhu, Xinyu
    Li, Bo
    Zhang, Xinyu
    Jiang, Yujin
    Huang, Yikeng
    Li, Chenxin
    Zheng, Zhi
    Zhang, Yili
    Zhu, Bei
    Zhao, Shuzhi
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [37] External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank
    Saunders, Catherine L.
    Kilian, Britt
    Thompson, Deborah J.
    McGeoch, Luke J.
    Griffin, Simon J.
    Antoniou, Antonis C.
    Emery, Jon D.
    Walter, Fiona M.
    Dennis, Joe
    Yang, Xin
    Usher-Smith, Juliet A.
    CANCER PREVENTION RESEARCH, 2020, 13 (06) : 509 - 520
  • [38] The contribution of rare and common genetic variants to risk of prostate cancer and second primary cancer after prostate in the UK Biobank
    Beebe-Dimmer, Jennifer Lynn
    Snyder, Nathan
    Schwartz, Ann G.
    Wei, Jun
    Shi, Zhuqing
    Tran, Huy
    Zheng, Lily
    Shevach, Jeffrey
    Cooney, Kathleen A.
    Xu, Jianfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Risk Factors Associated with Pancreatic Cancer in the UK Biobank Cohort
    Ke, Te-Min
    Lophatananon, Artitaya
    Muir, Kenneth R.
    CANCERS, 2022, 14 (20)
  • [40] Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study
    Messerli, Franz H.
    Bavishi, Chirag
    Messerli, Adrian W.
    Siontis, George C. M.
    EUROPEAN HEART JOURNAL, 2021, 42 (41) : 4282 - 4282